Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $15.80.
TNYA has been the topic of a number of research reports. SVB Leerink began coverage on Tenaya Therapeutics in a report on Thursday, November 30th. They set an “outperform” rating and a $7.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Thursday, November 30th.
Tenaya Therapeutics Stock Down 0.4 %
Hedge Funds Weigh In On Tenaya Therapeutics
A number of institutional investors have recently made changes to their positions in TNYA. Jane Street Group LLC bought a new position in Tenaya Therapeutics in the fourth quarter worth about $25,000. Balyasny Asset Management LLC bought a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth approximately $29,000. Barclays PLC boosted its position in Tenaya Therapeutics by 70.5% during the 4th quarter. Barclays PLC now owns 15,279 shares of the company’s stock valued at $31,000 after purchasing an additional 6,319 shares during the period. Tower Research Capital LLC TRC grew its stake in Tenaya Therapeutics by 162.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 12,891 shares of the company’s stock worth $33,000 after buying an additional 7,986 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Tenaya Therapeutics in the third quarter worth $38,000. 70.22% of the stock is owned by institutional investors and hedge funds.
Tenaya Therapeutics Company Profile
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy.
- Five stocks we like better than Tenaya Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 attractive stocks that insiders are buying
- The How and Why of Investing in Gold Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in EV Charging Stations
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.